Caspase-1 inhibitors, such as VX-765, have shown effectiveness in reducing IL-1β-mediated inflammation, indicating potential significance for conditions like SLE and IBD where inflammasome activation plays a key pathogenic role [31,33]. The gene discussed is CASP1; the disease is inflammatory bowel disease.